Novartis (NVS) Scheduled to Post Earnings on Tuesday

Novartis (NYSE:NVS) will be posting its quarterly earnings results before the market opens on Tuesday, October 29th. Analysts expect Novartis to post earnings of $1.91 per share for the quarter.

Novartis Price Performance

NVS stock opened at $115.76 on Tuesday. The company has a market capitalization of $236.61 billion, a P/E ratio of 14.67, a price-to-earnings-growth ratio of 1.70 and a beta of 0.57. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.72 and a current ratio of 0.93. Novartis has a 52-week low of $92.19 and a 52-week high of $120.92. The business has a 50-day simple moving average of $116.39 and a two-hundred day simple moving average of $108.22.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on NVS. Barclays upgraded Novartis to a “strong sell” rating in a research note on Monday, June 24th. Jefferies Financial Group cut shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 3rd. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $121.00 price target (up previously from $119.00) on shares of Novartis in a report on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a report on Friday, July 19th. Finally, Bank of America cut shares of Novartis from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $135.00 to $130.00 in a report on Wednesday, September 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $120.70.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.